- Home
- RLX vs IOVA Comparison
RLX vs IOVA Comparison
Compare RLX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLX | IOVA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 968.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLX | IOVA |
|---|---|---|
| Price | $2.27 | $2.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $2.25 | ★ $10.45 |
| AVG Volume (30 Days) | 1.7M | ★ 11.3M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | ★ 19.33 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $459,694,770.00 | $250,425,000.00 |
| Revenue This Year | $63.02 | $60.71 |
| Revenue Next Year | $24.72 | $59.52 |
| P/E Ratio | $27.49 | ★ N/A |
| Revenue Growth | 51.58 | ★ 175.62 |
| 52 Week Low | $1.66 | $1.64 |
| 52 Week High | $2.84 | $8.15 |
Technical Indicators
Market Signals| Indicator | RLX | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 69.24 |
| Support Level | $2.26 | $2.08 |
| Resistance Level | $2.33 | $2.60 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 5.21 | 87.36 |
Price Performance
Historical ComparisonAbout RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.